Pfizer Venture Investments (investor - Corporate Investor)
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc, was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.
With a $50M annual budget for private investments, PVI may invest up to $10M per round in selected companies in any stage of development, with a strong focus on growth stage opportunities. Other investments, including fund investing, spinout opportunities, and PIPEs will also be considered as appropriate. We actively manage our current portfolio and are seeking to make new investments.

Showing 3 of 18 tracked investments in:
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Pfizer Venture Investments mostly invests with:
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Investors with similar profile to Pfizer Venture Investments
Name | Criteria | |
---|---|---|
![]() |
V-Bio Ventures
83%
|
|
![]() |
Novartis Venture Fund
83%
|
|
![]() |
ABB Technology Ventures (ATV)
83%
|
|
![]() |
Aviva Ventures
83%
|
|
![]() |
Base10 Partners
83%
|
|
![]() |
Adjuvant Capital
83%
|
|
![]() |
Icos Capital Management
83%
|
|
![]() |
Expedition Growth Capital
83%
|
|
![]() |
Korys
83%
|
|
![]() |
Yabeo
83%
|
|